– Significant unmet need for safe and effective oral therapies in UC for patients with inadequate response, loss of response or intolerance to conventional or advanced therapies SAN DIEGO--(BUSINESS ...
- Significant unmet need for new effective therapies exists in ulcerative colitis - ELEVATE UC clinical trial sites continue to initiate SAN DIEGO, June 17, 2019 /PRNewswire/ -- Arena Pharmaceuticals, ...
SAN DIEGO--(BUSINESS WIRE)--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has completed full enrollment of the Phase 3 ELEVATE UC 52 trial evaluating the safety and efficacy of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results